Aktis Oncology (NASDAQ:AKTS) and Valneva (NASDAQ:VALN) Head-To-Head Review

Aktis Oncology (NASDAQ:AKTS) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Aktis Oncology and Valneva”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50 million	144.30	-$63.73 million	($0.82)	-21.28
Valneva	$197.56 million	2.83	-$130.33 million	($2.11)	-2.78

Aktis Oncology has higher earnings, but lower revenue than Valneva. Aktis Oncology is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aktis Oncology and Valneva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1	0	9	1	2.91
Valneva	2	0	1	0	1.67

Aktis Oncology presently has a consensus price target of $35.62, indicating a potential upside of 104.15%. Valneva has a consensus price target of $9.30, indicating a potential upside of 58.43%. Given Aktis Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Aktis Oncology is more favorable than Valneva.

Insider and Institutional Ownership

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aktis Oncology and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Valneva	-110.33%	-153.20%	-39.50%

Summary

Aktis Oncology beats Valneva on 11 of the 13 factors compared between the two stocks.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

About Valneva

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.